Research programme: infectious and inflammatory disease therapeutics - Oncology Research InternationalAlternative Names: ORILF
Latest Information Update: 20 Jul 2016
At a glance
- Originator Oncology Research International
- Mechanism of Action Angiogenesis inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Research Viral infections
Most Recent Events
- 20 Jul 2016 Early research in Viral infections in Australia (unspecified route)